Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Drugs

  • Print
  • Share
  • E-mail
-

FDA Drug Safety Newsletter - Volume 2, Number 2, 2009

This publication provides postmarketing information to healthcare professionals to enhance communication of new drug safety information, raise awareness of reported adverse events, and stimulate additional adverse event reporting.
    

In This Issue
 

Editor's Note

Postmarket Reviews

Overview of off-label use and serious adverse events 

Reports of acute renal impairment and failure associated with once-yearly intravenous treatment for osteoporosis in postmenopausal women

Reports of medication errors and adverse events in a pediatric population

Erratum 

Lenalidominde and Serious Skin Reactions - Drug Safety Newsletter 2008; 1 (4); 43-6.

Drug Safety Communications

List of drug safety advisories posted on FDA’s Web site from December 1, 2008 through March 31, 2009, with related links

  Cover of Newsletter, including table of contents

U.S. Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
10903 New Hampshire Avenue White Oak Campus 
Silver Spring, MD 20993
Phone: 1-888-INFO-FDA (1-888-463-6332)

Acknowledgments:
Office of Surveillance and Epidemiology and Office of New Drugs

Renan A. Bonnel, PharmD, MPH
Senior Scientific Editor

Gregory D. Busse, PhD
Editor

Contributing Authors:
S.Christopher Jones, PharmD, MS (quinine)
Mark S. Miller, PharmD (zolendronic acid)

Art Direction and Design: Elena H. Ketelhut

We value your comments. Please let us know by reaching us at Comments. All text in the Drug Safety Newsletter is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.
-
-